AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 153 filers reported holding AIMMUNE THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.71 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $1,341,621,000 | +103.7% | 38,944 | -1.2% | 0.00% | – |
| Q2 2020 | $658,475,000 | +17.8% | 39,406 | +1.6% | 0.00% | – |
| Q1 2020 | $559,150,000 | -59.0% | 38,776 | -4.8% | 0.00% | -100.0% |
| Q4 2019 | $1,362,899,000 | +55.4% | 40,720 | -2.8% | 0.00% | 0.0% |
| Q3 2019 | $877,113,000 | +2.6% | 41,887 | +2.1% | 0.00% | 0.0% |
| Q2 2019 | $854,536,000 | +56.9% | 41,044 | +68.4% | 0.00% | – |
| Q1 2019 | $544,714,000 | +9.0% | 24,372 | +16.6% | 0.00% | – |
| Q4 2018 | $499,928,000 | -12.3% | 20,900 | 0.0% | 0.00% | – |
| Q3 2018 | $570,152,000 | +1.5% | 20,900 | 0.0% | 0.00% | – |
| Q2 2018 | $562,001,000 | -21.0% | 20,900 | -6.5% | 0.00% | -100.0% |
| Q1 2018 | $711,306,000 | +111.3% | 22,347 | +151.1% | 0.00% | – |
| Q4 2017 | $336,598,000 | -95.3% | 8,900 | -96.9% | 0.00% | -100.0% |
| Q3 2017 | $7,214,460,000 | – | 291,023 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 3,967,900 | $42,933,000 | 29.35% |
| TLP GROUP LLC | 2,833,285 | $30,656,000 | 20.86% |
| Aisling Capital LLC | 2,990,000 | $32,352,000 | 7.64% |
| Vivo Capital, LLC | 763,009 | $8,256,000 | 2.26% |
| RA Capital Management | 1,292,940 | $13,990,000 | 1.94% |
| Foresite Capital Management III, LLC | 235,020 | $2,543,000 | 1.74% |
| Palo Alto Investors LP | 325,599 | $3,523,000 | 0.27% |
| Rock Springs Capital Management LP | 293,000 | $3,170,000 | 0.24% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 332,625 | $3,599,000 | 0.20% |
| Virtus ETF Advisers LLC | 19,501 | $211,000 | 0.16% |